Roche Acquires Carmot Therapeutics for $2.7 Billion Upfront
December 4, 2023
Carmot Therapeutics entered into a definitive merger agreement to be acquired by Roche for $2.7 billion upfront, with up to $400 million in potential milestone payments. Carmot’s shareholders will receive $2.7 billion in cash at closing, and Carmot and its employees will join the Roche Group’s Pharmaceuticals Division.
- Buyers
- Roche
- Targets
- Carmot Therapeutics
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.